Chris M. Calcaterra Sells 8,771 Shares of Glaukos Corp (GKOS) Stock

Glaukos Corp (NYSE:GKOS) COO Chris M. Calcaterra sold 8,771 shares of Glaukos stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $44.01, for a total value of $386,011.71. Following the completion of the transaction, the chief operating officer now owns 248,771 shares of the company’s stock, valued at approximately $10,948,411.71. The sale was disclosed in a document filed with the SEC, which is available at this link.

Glaukos traded down $0.77, reaching $43.02, during midday trading on Friday, Marketbeat.com reports. 416,700 shares of the company traded hands, compared to its average volume of 537,503. Glaukos Corp has a twelve month low of $23.08 and a twelve month high of $44.76. The firm has a market capitalization of $1.46 billion, a P/E ratio of 838.40 and a beta of 1.08.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, May 9th. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02. Glaukos had a positive return on equity of 1.22% and a negative net margin of 2.25%. The business had revenue of $40.10 million during the quarter, compared to analyst estimates of $37.63 million. During the same quarter in the previous year, the firm posted $0.02 EPS. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. sell-side analysts forecast that Glaukos Corp will post -0.4 EPS for the current fiscal year.



GKOS has been the subject of several research reports. Stephens reiterated a “buy” rating and issued a $36.00 target price on shares of Glaukos in a research report on Thursday, March 1st. Stifel Nicolaus decreased their target price on Glaukos from $42.00 to $39.00 and set a “buy” rating for the company in a research report on Monday, February 26th. ValuEngine upgraded Glaukos from a “sell” rating to a “hold” rating in a research report on Friday, April 27th. Cantor Fitzgerald set a $43.00 target price on Glaukos and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Finally, William Blair reiterated an “outperform” rating on shares of Glaukos in a research report on Thursday, March 1st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Glaukos presently has an average rating of “Buy” and an average price target of $41.13.

A number of large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its stake in Glaukos by 10.2% during the 1st quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock valued at $918,000 after acquiring an additional 2,746 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Glaukos by 37.2% during the 1st quarter. Handelsbanken Fonder AB now owns 258,000 shares of the medical instruments supplier’s stock valued at $7,954,000 after acquiring an additional 70,000 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its stake in Glaukos by 53.0% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 252,900 shares of the medical instruments supplier’s stock valued at $7,797,000 after acquiring an additional 87,600 shares in the last quarter. UBS Group AG raised its stake in Glaukos by 14,833.6% during the 1st quarter. UBS Group AG now owns 42,710 shares of the medical instruments supplier’s stock valued at $1,316,000 after acquiring an additional 42,424 shares in the last quarter. Finally, Lord Abbett & CO. LLC raised its stake in Glaukos by 77.2% during the 1st quarter. Lord Abbett & CO. LLC now owns 151,816 shares of the medical instruments supplier’s stock valued at $4,680,000 after acquiring an additional 66,153 shares in the last quarter.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply